<DOC>
	<DOCNO>NCT02583542</DOCNO>
	<brief_summary>Selumetinib ( AZD6244 ) AZD2014 two new anti-cancer treatment AstraZeneca develop ; yet approve clinical use . Selumetinib ( AZD6244 ) drug act block protein call MEK , link development growth multiple cancer . AZD2014 drug block protein call mTOR involved growth spread cancer . Blocking action either MEK mTOR alone may slow stop cancer grow . Combining drug may make cancer sensitive Selumetinib ( AZD6244 ) AZD2014 use alone therefore dual treatment may lead increase anti-tumour effect . Although Selumetinib ( AZD6244 ) AZD2014 give alone combination anti-cancer drug test people advanced cancer , specific combination Selumetinib ( AZD6244 ) AZD2014 use people . Therefore Phase 1b ( Dose Escalation Phase ) determine recommend dose use Phase IIa ( Dose Expansion Phase ) . Efficacy , progression free survival , duration response , overall survival , assess patient triple-negative breast cancer , Non small cell lung cancer within Phase IIa .</brief_summary>
	<brief_title>A Study AZD2014 Combination With Selumetinib Patients With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>1 . Written inform consent prior admission study 2 . Age ≥18 year 3 . ECOG performance status 0 1 4 . Life expectancy ≥12 week 5 . Patients must least one lesion , previously irradiate , measure accurately baseline ≥10 mm long diameter ( except lymph node must short axis ≥15 mm ) compute tomography ( CT ) magnetic resonance imaging ( MRI ) suitable accurate repeat measurement 6 . Radiological clinical evidence disease progression 7 . Formalin fix , paraffin embed tumour sample primary recurrent cancer must available central test 8 . Adequate haematologic end organ function , define follow laboratory result obtain within 7 day prior first study treatment : ANC ≥ 1.5 x 109/l ( without granulocyte colonystimulating factor support within 2 week prior first study treatment ) Platelet count ≥ 100 x 109/l ( without transfusion within 2 week prior first study treatment ) Haemoglobin ≥ 9 g/dl ( transfusion permit establish target haemoglobin level prior first study treatment ) Serum creatinine ≤1.5 time upper limit normal ( ULN ) calculate creatinine clearance ≥ 50 ml/min Bilirubin level ≤1.5 x ULN ( patient know Gilbert disease bilirubin level ≤ 3 x ULN may enrol ) AST ALT &lt; 2.5 x ULN &lt; 5 x ULN presence liver metastases Alkaline phosphatase ( ALP ) &lt; 2.5 x ULN &lt; 5 x ULN presence liver and/or bone metastasis INR aPTT ≤1.5 x ULN ; apply patient receive therapeutic anticoagulation ; patient receive therapeutic anticoagulation stable dose . Female patient childbearing potential eligible , provide negative serum urine pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible . All patient reproductive potential must agree use adequate contraception begin two week first dose investigational product three month discontinuation treatment . Adequate contraception method include : intrauterine device [ IUD ] , birth control pills unless clinically contraindicate , barrier device . Inclusion Criteria unique Dose Escalation Part ( phase Ib part ) : 1 . Histologically cytologically advance solid tumour limit : Tumour type frequent activation MAPK and/or PI3K pathway ( pancreatic , thyroid , endometrial , renal , breast ovarian carcinoma , colorectal cancer , NSCLC melanoma ) OR Tumours know alteration ≥1 gene involve PI3K/AKT/mTOR Ras/MEK pathway signalling , : KRAS , NRAS , BRAF , PIK3CA , PTEN , AKT , LKB1 , EGFR , FGFR , HER2 , MET , RET , KIT , NF1 2 . Metastatic locally advance disease , refractory conventional treatment conventional therapy exist ; locally recurrent disease must amenable resection curative intent ( patient consider suitable surgical ablative technique follow potential downstaging study treatment eligible ) . Inclusion Criteria unique lung cancer dose expansion cohort ( phase IIa part ) : 1 . Histologically confirm NSCLC 2 . Stage III disease unsuitable radiochemotherapy Stage IV disease recurrent NSCLC ; recurrent disease must amenable resection radical radiotherapy curative intent . 3 . Prior chemotherapy and/or , indicated/accessible , EGFRdirected ALKdirected therapy advance disease Inclusion Criteria unique TNBC dose expansion cohort ( Phase IIa ) : 1 . Histologically confirm TNCB define tumour cell : Negative ER &lt; 1 % tumour cell positive ER IHC IHC score ( Allred ) ≤2 Negative PR &lt; 1 % tumour cell positive PR IHC IHC score ( Allred ) ≤2 PR unknown , Negative HER2 0 , 1+ 2+ intensity IHC evidence amplification ISH . 2 . Metastatic locally recurrent disease ; locally recurrent disease must amenable resection curative intent ( patient consider suitable surgical ablative technique follow potential downstaging study treatment eligible ) . 3 . Prior chemotherapy advance disease 1 . Symptomatic CNS involvement CNS involvement require steroid therapy ; patient treat brain metastasis asymptomatic clinically stable 1 month eligible protocol participation 2 . Prior chemotherapy , biological therapy , radiation therapy , immunotherapy , anticancer agent investigational agent within 14 day start study treatment ( include palliative radiotherapy focal site ) 3 . Any unresolved toxicity &gt; CTCAE Grade 1 previous anticancer therapy , exception alopecia 4 . Current refractory nausea vomiting , chronic gastrointestinal disease inability swallow formulate product previous significant bowel resection would preclude adequate absorption study medication 5 . Significant cardiovascular disease , ; History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty/stenting/bypass graft within past 6 month . Uncontrolled angina ( Canadian Cardiovascular Society grade IIIV despite medical therapy ) History symptomatic congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Classes IIIV Left ventricular ejection fraction ( LVEF ) &lt; 55 % measure echocardiography Severe cardiac arrhythmia require medication severe conduction abnormality ( unless compensate ventricular pacemaker ) ; atrial fibrillation ventricular rate &gt; 100 bpm ECG rest Poorly control hypertension ( rest diastolic blood pressure &gt; 115 mmHg ) Clinically significant valvular disease , cardiomegaly , ventricular hypertrophy , prior current cardiomyopathy 6 . QTc prolongation define QTc interval &gt; 470 msec 7 . Concomitant medication know prolong QT interval 8 . Patients receive concomitant immunosuppressive agent chronic systemic corticosteroid ( ≥ 10 mg prednisolone equivalent dose antiinflammatory corticosteroid ) use ≥ 28 day time study entry except case outline : Topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local injection ( e.g . intraarticular ) allow . Patients stable low dose ( &lt; 10 mg prednisolone equivalent dose antiinflammatory corticosteroid ) corticosteroid least two week registration allow 9 . Evidence interstitial fibrotic lung disease ( bilateral , diffuse , parenchymal lung disease ) 10 . Clinically significant abnormality glucose metabolism define follow Diagnosis diabetes mellitus type I II ( irrespective management ) . Glycosylated haemoglobin ( HbA1C ) ≥ 8.0 % screening ( 64 mmol/mol ) ( conversion equation HbA1C [ IFCCHbA1C ( mmol/mol ) = [ DCCTHbA1C ( % ) 2.15 ] x 10.929 ) Fasting Plasma Glucose ≥ 7.0mmol/L ( 126 mg/dL ) screening . Fasting define caloric intake least 8 hour . 11 . Ophthalmological condition follow : Intraocular pressure &gt; 21 mmHg , uncontrolled glaucoma ( irrespective intraocular pressure ) Current past history central serous retinopathy retinal vein occlusion 12 . Exposure potent moderate inhibitor inducer CYP3A4/5 take within state washout period first dose study treatment Inhibitors ( competitive ) : ketoconazole , itraconazole , indinavir , saquinovir , nelfinavir , atazanavir , amprenavir , fosamprenavir , troleandomycin , telithromycin , fluconazole , nefazodone , cimetidine , aprepitant , miconazole , fluvoxamine , Pglycoprotein , grapefruit juice , seville orange ( 1 week minimum washout period ) , amiodarone ( 27 week minimum washout period ) Inhibitors ( time dependent ) : erythromycin , clarithromycin , verapamil , ritonavir , diltiazem ( 2 week minimum washout period ) Inducers : phenytoin , rifampicin , St. John 's Wort , carbamazepine , dexamethasone , primidone , griseofulvin , carbamazepine , barbiturate , troglitazone , pioglitazone , oxcarbazepine , nevirapine , efavirenz , rifabutin ( 3 week minimum washout period ) phenobarbitone ( 5 week minimum washout period ) 13 . Exposure potent moderate inhibitor inducer CYP2C8 within state washout period first dose study treatment Inhibitors : Gemfibrozil , trimethoprim , glitazones , montelukast , quercetin ( 1 week minimum washout period ) Inducers : Rifampicin ( 3 week minimum washout period ) 14 . Exposure sensitive narrow therapeutic range substrate drug metabolise enzyme CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 drug transporter Pgp ( MDR1 ) BCRP within appropriate washout period first dose study treatment 15 . Active second malignancy ( except nonmelanomatous skin cancer ) : active secondary malignancy define current need cancer therapy high possibility ( &gt; 30 % ) recurrence study . 16 . Any evidence severe uncontrolled systemic disease , active infection , active bleeding diatheses renal transplant , include patient know hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) 17 . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory finding , investigator 's opinion , give reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result , render patient high risk treatment complication interfere obtain informed consent . 18 . Psychological , familial , sociological geographical condition permit compliance study protocol . 19 . Concurrent treatment experimental drug participation another clinical trial investigational drug ≤30 day prior study entry depend halflife investigational drug and/or guidance issue TORCMEK IMP manufacturer . Please contact TORCMEK Coordinating team information . Exclusion Criteria unique dose expansion cohort ( phase IIa part ) : 1 . Prior treatment PI3K inhibitor , AKT inhibitor , mTOR inhibitor MEK , Ras Raf inhibitor . 2 . Prior radiotherapy indicator lesion ( ) ; Newly arise lesion previously irradiate area accept .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>breast</keyword>
	<keyword>lung</keyword>
	<keyword>squamous</keyword>
	<keyword>KRAS</keyword>
	<keyword>AZD</keyword>
	<keyword>selumetinib</keyword>
</DOC>